Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 37-48 of 77 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 37-48 of 77 studies
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of VX-659 combination drug in adults with cystic fibrosis , protocol number Vertex VX16-659-101This study evaluated the safety, tolerability and effectiveness of the drug VX-659 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
8 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis , protocol number VX-445-001This study evaluated the safety, tolerability and effectiveness of the drug VX-445 in combination with tezacaftor/ivacaftor (Symdeko®) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
12 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2a study of Galapagos GLPG2222 in adults with CF , protocol number GLPG2222-CL-202This study evaluated the safety and effectiveness of the CFTR modulator GLPG2222. This study was for people with CF who have two copies of the F508del mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
5
-
Length of Participation:
10 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function , protocol number Vertex VX-661-108This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) versus ivacaftor alone versus placebo. This study was for people with CF who have one copy of the F508del CFTR mutation and a CFTR mutation associated with residual CFTR function.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
12
-
Length of Participation:
33 weeks
-
-
Restore CFTR ProteinCompleted with Results
VX 809 and ivacaftor in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation (105) , protocol number Vertex VX-809-105This was an open-label follow-on study that evaluated the safety and efficacy of lumacaftor in combination with ivacaftor (Orkambi®) in people with CF, 12 years and older and who have two copies of the F508del genetic mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
96 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex Lumacaftor (VX-809) and Ivacaftor in Children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation , protocol number Vertex VX13-809-011bThis was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (Orkambi®). This study was for younger children with CF who have two copies of the F508del CFTR mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
11
-
Length of Participation:
27 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of CTP-656 in adults with CF who are currently taking ivacaftor (Kalydeco®) , protocol number Concert CTP-656This study evaluated the safety and effectiveness of the drug CTP-656 in adults with CF who have a gating mutation and are currently taking ivacaftor (Kalydeco®).
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
60% or greater
-
Number of Visits:
6
-
Length of Participation:
7 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of tezacaftor (VX-661) combination drug in children with cystic fibrosis , protocol number Vertex VX15-661-113This study evaluated the safety and tolerability of the drug tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) in children with CF. This study was for children who have two copies of the F508del mutation or one copy of F508del and a second mutation that is either residual function or results in a gating defect and responds to ivacaftor.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
28 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of VX-440 combination drug in people with cystic fibrosis , protocol number Vertex VX-440-101This study evaluated the safety and tolerability of the drug VX-440 in combination with ivacaftor and tezacaftor (VX-661) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
11
-
Length of Participation:
57 days
-
-
Restore CFTR ProteinCompleted with Results
Phase 2 study of VX-152 combination drug in people with cystic fibrosis , protocol number Vertex VX-152-102This study evaluated the safety and tolerability of the drug VX-152 in combination with ivacaftor and tezacaftor (VX-661) in people who either have two copies of the F508del CFTR mutation or have one copy of F508del and one copy of a minimal function CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
10
-
Length of Participation:
16 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of lumacaftor/ivacaftor in children with CF , protocol number Vertex VX15-809-115This study evaluated the safety and effectiveness of lumacaftor in combination with ivacaftor (Orkambi®) in people who have two copies of the F508del mutation.
-
Age:
2 Years to 5 Years
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
11
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation , protocol number Vertex VX-661-111This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
6
-
Length of Participation:
60 days
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More